ReviewTherapeutic advances in hematology2016
Targeting the leukemia-stroma interaction in acute myeloid leukemia: rationale and latest evidence.
Review in Therapeutic advances in hematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 53 citations in OpenAlex.
- Decoding GPCR signaling reprogramming in cancer: molecular mechanisms and therapeutic implications.Molecular medicine (Cambridge, Mass.) · 2026Review
- Remodeling of the bone marrow microenvironment during acute myeloid leukemia progression.Annals of translational medicine · 2024Review
- Dexamethasone-Induced Fatty Acid Oxidation and Autophagy/Mitophagy Are Essential for T-ALL Glucocorticoid Resistance.Cancers · 2023Article
- Inhibition of IRE1α RNase activity sensitizes patient-derived acute myeloid leukaemia cells to proteasome inhibitors.Journal of cellular and molecular medicine · 2022Article
- Molecular Systems Architecture of Interactome in the Acute Myeloid Leukemia Microenvironment.Cancers · 2022Review
- Upregulation of hsa-miR-625-5p Inhibits Invasion of Acute Myeloid Leukemia Cancer Cells through ILK/AKT Pathway.Cell journal · 2022Article
- Genetic and Transcriptional Contributions to Relapse in Normal Karyotype Acute Myeloid Leukemia.Blood cancer discovery · 2022Article
- Pharmacological inhibition of Carbonic Anhydrase IX and XII to enhance targeting of acute myeloid leukaemia cells under hypoxic conditions.Journal of cellular and molecular medicine · 2021Article
- Harnessing organs-on-a-chip to model tissue regeneration.Cell stem cell · 2021Review
- Immune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Review
- Insights Into Bone Marrow Niche Stability: An Adhesion and Metabolism Route.Frontiers in cell and developmental biology · 2021Review
- Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment.Blood cancer journal · 2020Article
- The Interplay between MicroRNAs and the Components of the Tumor Microenvironment in B-Cell Malignancies.International journal of molecular sciences · 2020Review
- Review
- New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML).Children (Basel, Switzerland) · 2020Review
- Redistribution, homing and organ-invasion of neoplastic stem cells in myeloid neoplasms.Seminars in cancer biology · 2020Review
- Therapy-related acute myeloid leukemia and its prevention.American journal of blood research · 2020Review
- Denatonium as a Bitter Taste Receptor Agonist Modifies Transcriptomic Profile and Functions of Acute Myeloid Leukemia Cells.Frontiers in oncology · 2020Article
- Relationship between CXC chemokine receptor 4 expression and prognostic significance in acute myeloid leukemia.Medicine · 2019Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The concept of 'niche' has become a focus of attention in hematologic malignancies including acute myeloid leukemia (AML). Similar to normal hematopoietic stem cells, AML cells interact both anatomically and functionally with the stroma within the marrow microenvironment. These interactions have a critical role in the development, progression, and relapse of AML. Chemotherapy resistance is another feature that is at least partially related to AML-stroma interactions. The evidence for safety and efficacy of agents targeting AML-niche interactions is currently limited to preclinical and early phase clinical studies. Examples include CXCR4 inhibitors, hypoxia-inducible agents, and adhesion molecule inhibitors. Agents that target AML-stroma interactions differ from mutation-specific approaches that tend to be limited due to within-individual and between-individual genetic heterogeneity. These agents may be used alone or as chemosensitizers in AML. This novel and rapidly advancing strategy is likely to become an important part of our armamentarium of anti-leukemia treatments in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.